156 related articles for article (PubMed ID: 21225568)
1. [Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology].
Rabenstein T; Fromm MF; Zolk O
Z Gastroenterol; 2011 Feb; 49(2):211-24. PubMed ID: 21225568
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Cottreau J; Baker SF; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
Gerard L; Garey KW; DuPont HL
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
[TBL] [Abstract][Full Text] [Related]
4. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
5. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.
Koo HL; DuPont HL
Curr Opin Gastroenterol; 2010 Jan; 26(1):17-25. PubMed ID: 19881343
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin: a review of its use in the management of traveller's diarrhoea.
Robins GW; Wellington K
Drugs; 2005; 65(12):1697-713. PubMed ID: 16060706
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.
Scarpignato C; Pelosini I
Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748
[TBL] [Abstract][Full Text] [Related]
9. New trends in non-absorbable antibiotics in gastrointestinal disease.
Di Febo G; Calabrese C; Matassoni F
Ital J Gastroenterol; 1992; 24(9 Suppl 2):10-3. PubMed ID: 1486193
[TBL] [Abstract][Full Text] [Related]
10. Biologic properties and clinical uses of rifaximin.
DuPont HL
Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW
Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin pharmacology and clinical implications.
Ojetti V; Lauritano EC; Barbaro F; Migneco A; Ainora ME; Fontana L; Gabrielli M; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):675-82. PubMed ID: 19442033
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.
Di Stefano M; Malservisi S; Veneto G; Ferrieri A; Corazza GR
Aliment Pharmacol Ther; 2000 May; 14(5):551-6. PubMed ID: 10792117
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.
Lauritano EC; Gabrielli M; Lupascu A; Santoliquido A; Nucera G; Scarpellini E; Vincenti F; Cammarota G; Flore R; Pola P; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2005 Jul; 22(1):31-5. PubMed ID: 15963077
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin for the treatment of irritable bowel syndrome.
Cremonini F; Lembo A
Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin: beyond the traditional antibiotic activity.
Calanni F; Renzulli C; Barbanti M; Viscomi GC
J Antibiot (Tokyo); 2014 Sep; 67(9):667-70. PubMed ID: 25095806
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
Gasztonyi B; Hunyady B
Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494
[TBL] [Abstract][Full Text] [Related]
20. Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin.
Di Stefano M; Corazza GR
Chemotherapy; 2005; 51 Suppl 1():103-9. PubMed ID: 15855754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
